ライフサイエンスコーパス: biomarker

1 explore the use of glutamine as a potential biomarker.

2 sitivity and serving as a treatment efficacy biomarker.

3 which has precluded its use as a predictive biomarker.

4 68)Ga-PSMA-HBED-CC as a quantitative imaging biomarker.

5 ly applicable to the detection of many other biomarkers.

6 lternative to biopsies for detecting disease biomarkers.

7 athologic change (ADNC) was assessed for all biomarkers.

8 fer opportunities for improved therapies and biomarkers.

9 human malignancies and represent predictive biomarkers.

10 o estimate actual intake without nutritional biomarkers.

11 n order to define evolution-resistant cancer biomarkers.

12 eening with protocol biopsy was favored over biomarkers.

13 ing CAD loci and to identify novel molecular biomarkers.

14 R by a significant reduction in inflammation biomarkers.

15 d by endoscopy, cross-sectional imaging, and biomarkers.

16 onder groups and correlated with OCT imaging biomarkers.

17 a widely used approach for detecting genomic biomarkers.

18 ated whether miRNAs have potential as NTM-PD biomarkers.

19 ors for the detection of Parkinson's disease biomarkers.

20 microorganisms with as-yet-unknown molecular biomarkers.

21 ted excitement for their potential as cancer biomarkers.

22 ed causal antigens and lack of gold-standard biomarkers.

23 search has been conducted to identify sepsis biomarkers.

24 cted between lipidomic features and clinical biomarkers.

25 Prospective studies are required to validate biomarkers.

26 ere, we present a resource of SaB prognostic biomarkers.

27 nucleic acid detection for low-abundance DNA biomarkers.

28 avenue to develop an alternative to natural biomarkers.

29 pathogenesis and the development of 5hmC as biomarkers.

30 kine storm, and elevations of cardiac injury biomarkers.

31 accurately than previously identified cancer biomarkers.

32 analyses and compared with that of CSF core biomarkers Abeta42, P-tau and T-tau.

33 ere, we test E(p) using a variety of general biomarkers along a transect taken from a naturally occur

34 bine datasets, including microbial necromass biomarker amino sugars and SOC, from two long-term agric

35 ty of molecules (e.g. proteins, dyes, drugs, biomarkers, amino acids) based on application of the alt

36 gamma power abnormalities are a translatable biomarker among species and demonstrate the utility of F

37 found higher levels of systemic inflammatory biomarkers among PLHIV who were virally suppressed, and

38 We performed a comprehensive immunomolecular biomarker analysis to characterize the role of immune ce

39 ch is something usual in biomedical data and biomarkers analysis.

40 independent cohorts: the Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL)

41 Further clinical, neuroradiological, biomarker and neuropathological studies are essential to

42 Employing YKL-40 as a resistance biomarker and ZEB1 as a target to prevent resistance cou

43 iographic abnormalities, higher inflammatory biomarkers and an increased prevalence of major echocard

44 The serum metabolome contains a plethora of biomarkers and causative agents of various diseases, som

45 tcomes should help identify novel predictive biomarkers and features as well as therapeutically relev

46 non-targeted urine metabolomics to discover biomarkers and improve risk prediction for T2D.

47 Time 1 biomarkers and longitudinal measurements were compared f

48 ancer-associated blood vessels to find novel biomarkers and mechanisms involved in tumor-associated a

49 ents, both in terms of diagnostic/prognostic biomarkers and novel pharmacological targets.

50 le-cell resolution, revealing new diagnostic biomarkers and potential therapeutic targets for age-rel

51 some important glycoproteins, such as tumor biomarkers and recombinant drug proteins.

52 features of neoplasia, and have been used as biomarkers and therapeutic targets for multiple cancers.

53 ntial to be promising diagnostic, prognostic biomarkers and therapeutic targets in breast cancer.

54 and cholinergic tone, and may suggest novel biomarkers and therapeutic targets.

55 e in PCa, which could be exploited for novel biomarkers and therapies.

56 rstanding of AD pathogenesis and lead to new biomarkers and treatment targets.

57 nd antidepressant response at the molecular, biomarker, and psychological levels.

58 h differences in clinical features, fibrosis biomarkers, and functional performance.

59 on of response (DOR), clinical-benefit rate, biomarkers, and safety.

60 nt molecules in the presence of specific IgG biomarker antibodies.

61 The most common biomarker approved by the FDA (United States Food and Dr

62 Various biomarkers are available to support the diagnosis of neu

63 Elevated levels of inflammatory biomarkers are consistently associated with chronic cond

64 ly progressive, and objective, imaging-based biomarkers are critically needed.

65 bling T cell reactivation; however, response biomarkers are required, as most patients do not benefit

66 ile our two late DUX4 target gene expression biomarkers associate with macroscopic inflammation detec

67 utcomes, the S5 classifier was the strongest biomarker associated with regression vs progression.

68 Biomarkers associated with incident TB overlapped with t

69 Cluster analysis identified 4 serum biomarker-based clusters, 3 of which (clusters B, C, and

70 vant to both the need and COU, assessment of biomarker benefits and risks relevant to the COU, and th

71 fulness not only as screening and predictive biomarkers, but also in capturing the pathogenesis of Al

72 y focused on the discovery and validation of biomarkers, but the systematic analysis of the nephropro

73 n affordable point-of-care detection of this biomarker can benefit millions suffering from these dise

74 tion and utilized it to search for molecular biomarkers causally associated with the risk of CAD with

75 egeneration (N) status as required by recent biomarker classification algorithms (A/T/N).

76 ics, as well as investigations of multimodal biomarker combinations across fluids, brain imaging and

77 espite pre-clinical data supporting the drug-biomarker combinations, current evidence shows that a li

78 estions such as the relative value of tissue biomarkers compared with magnetic resonance imaging.

79 r twice or thrice was cost effective only if biomarker cost was <$700.

80 Ideally, a biomarker could reliably and rapidly distinguish bacteri

81 Routine biomarkers could predict severity of appendicitis with h

82 hypothetical phase III trial, adjusting for biomarker covariates.

83 20), then in a second cohort where the IWG-2 biomarker criteria were applied (Alzheimer's disease = 3

84 atment with MSU-42011 did not increase these biomarkers, demonstrating a more favorable toxicity prof

85 ively impact the accuracy and sensitivity of biomarkers dependent on FAZ identification.

86 ntibody screening, custom assay development, biomarker detection, and protein profiling for diagnosti

87 rformed to select the optimal combination of biomarkers, diagnostic accuracy was determined using are

88 In contrast, T and N status biomarkers differed between amnestic and non-amnestic Al

89 treatment initiation to identify predictive biomarkers differentiating responders from nonresponders

90 o its ability to spatially resolve molecular biomarkers directly from sectioned tissues.

91 ied clinical studies, including glycan-based biomarker discovery and therapeutics.

92 To address this challenge, a biomarker discovery pipeline was developed to integrate

93 f prediction and classification and advances biomarker discovery.

94 gorithms represent a new era for noninvasive biomarker discovery.

95 erlying mechanisms and on the approaches for biomarkers discovery is also provided, including genetic

96 We demonstrate that the biomarkers do not show significant daily variation, and

97 miRNAs are considered efficient candidate biomarkers due to their high stability in tissues and bo

98 hint at implications for the preservation of biomarkers during tooth development.

99 On-chip microarray analysis of serum biomarkers (e.g., cardiac troponin I) afforded up to 130

100 tative correlation between the expression of biomarkers, EcPV2 infection and inflammation.

101 o are interested in finding salivary protein biomarkers, especially when they have identified candida

102 impairments do not seem to be accompanied by biomarker evidence of ongoing neuronal or astrocytic inj

103 bitumen can be sourced to the Dead Sea using biomarkers, evidencing a trade in this material from the

104 Aberrant biomarker expression stratified the cohorts into 3 disti

105 biomarkers, minimal (3 parameters); (3) OCT biomarkers, extended (7 parameters); and (4) CFP and OCT

106 educing model complexity and discovering key biomarkers, feature selection is also an effective metho

107 There is much still to learn in the fluid biomarker field in FTD, but the creation of large multin

108 have examined the gut microbiome as a novel biomarker for advanced fibrosis have only examined patie

109 We first established network stability as a biomarker for brain aging using two large-scale (n = 292

110 ivo data, potentially providing an important biomarker for cancer diagnosis and treatment.

111 ng creatinine and creatinine is an important biomarker for chronic kidney disease (CKD), we tested th

112 C5AC mucin can be used as a disease-relevant biomarker for conjunctiva GC health.

113 ession of PAX8 in cancer can also serve as a biomarker for diagnostic and prognostic purposes.

114 rch, evidence supports the role of WBP2 as a biomarker for early detection, prognosis, and companion

115 The elevated IgG4 levels may be a biomarker for efficacy of VIT in cMCD patients, as it co

116 e to AZD1775 and defined PTEN as a promising biomarker for efficient WEE1 cancer therapy.

117 spective investigation of APOE genotype as a biomarker for melanoma outcome and therapeutic response.

118 rocyte samples obtained at recruitment, as a biomarker for metal exposure from any source.

119 rly, our results revealed IGFALS as a useful biomarker for moderate-severe allergic asthma.

120 investigated the role of midkine as a cancer biomarker for the detection, prognosis, and management o

121 CTRP7, CTRP15 may serve as more suitable biomarker for the diagnosis of CAD patients, whereas CTR

122 tion in the HCC chromosome, as a circulating biomarker for this clinical setting.

123 , providing an alternate molecularly defined biomarker for this drug.

124 as been previously established as an imaging biomarker for tumor response.

125 permethylation in the cervix show promise as biomarkers for anal cancer screening in HIV+ and at-risk

126 a clinically translatable predictive cancer biomarkers for cancer patients.

127 The biosensor detected SDE1 biomarkers for citrus greening in plant tissue extracts

128 mics texture features can serve as potential biomarkers for determining BRAF mutation status and as p

129 ic, immunologic, metabolomics, and proteomic biomarkers for development of islet autoimmunity (IA) an

130 me points, we identified IL-17A and KLK-7 as biomarkers for disease severity and apremilast pharmacod

131 will allow for the identification of unique biomarkers for early AD.

132 mergence in typical development and identify biomarkers for early detection and tailored intervention

133 gests that optimal longitudinal neuroimaging biomarkers for future clinical treatment trials in Alzhe

134 Validation of noninvasive biomarkers for monitoring treatment response, tests for

135 We aimed to identify causal protein biomarkers for MPV and PLT among 71 CVD-related plasma p

136 veal the challenges of developing prognostic biomarkers for patients with IBD and the importance of t

137 outh, which may inform the identification of biomarkers for prognosis and treatment response.

138 itive and specific diagnostic and prognostic biomarkers for prostate cancer (PCa) are urgently needed

139 g in target selection, development of robust biomarkers for response prediction, and understanding an

140 ctor receptor-2 (HER2) are the three crucial biomarkers for the clinical diagnosis of breast cancer.

141 have reviewed available as well as promising biomarkers for this purpose in terms of the clinical nee

142 As circulating miRNAs are promising biomarkers for various diseases, we investigated whether

143 We identified a Raman biomarker from glycogen to distinguish iPSCs from their

144 ans and prevalences were estimated for lipid biomarkers from >=2005.

145 %, because the top discriminatory metabolite biomarkers from the optimised protocol remained discrimi

146 spects for detection of microbe-specific VOC biomarkers from two potential biowarfare agents.

147 e direct ultrasensitive detection of protein biomarkers from whole blood samples.

148 s for available tissue-based prostate cancer biomarkers geared toward patient selection for active su

149 Moreover, the biomarker gene expression signatures yielded leads for p

150 This biomarker generalized to a drug-free independent cohort

151 ation of brain regions and identification of biomarker genes for brain related phenotypes.

152 utational framework is developed to identify biomarker genes for lung cancer using gene expression pr

153 er RNA-Seq, where we identify novel putative biomarker genes in different tumors, and microarray and

154 res created using a set of five putative MDD biomarkers, genome-wide SNP data, and 27 clinical, demog

155 y liver index (FLI), a noninvasive steatosis biomarker, has recently drawn attention for its clinical

156 inical course and WHO grade exists, reliable biomarkers have been sought.

157 Biomarkers have emerged as powerful tools for the diagno

158 arison of metabolic profiles and for unknown biomarker identification that is complementary to high r

159 Biomarkers, if indicative of the underlying pathophysiol

160 drug-resistant and prognosis-related lncRNA biomarkers; (ii) 11 418 somatic mutation-ceRNA events fr

161 carcinoembryonic antigen (CEA, an important biomarker in colorectal cancer), integrated in the elect

162 ncluding gastric cancer, and is an important biomarker in drug discovery.

163 We evaluated serum biomarkers in 149 individuals; 77 (52%) pre-SOT and 72 (

164 ese subgroups requires the identification of biomarkers in biological samples, and serum proteomics i

165 plicable to various diseases with well-known biomarkers in diagnostics and monitoring, especially wit

166 To identify novel prognostic biomarkers in EOC, here we determined the expression of

167 requent, real-time, and accurate measures of biomarkers in epidermally-retrievable biofluids (e.g., s

168 latform for absolute quantitation of protein biomarkers in FFPE samples to meet the need of daily cli

169 quantitative detection of multiplex cardiac biomarkers in human serum to expedite medical decisions

170 ould also be taken into account as potential biomarkers in ICI therapy and they may have an impact on

171 cular hypertrophy (LVH) and elevated cardiac biomarkers in middle age are at high risk for the develo

172 pharmacokinetics of nilotinib, and measured biomarkers in participants with mild to moderate dementi

173 We examined neuroimaging-derived hippocampal biomarkers in subjects at clinical high risk (CHR) for p

174 We assessed the diagnostic values of serum biomarkers in the differential diagnosis between FTLD, A

175 spikes or spike ripples and might be useful biomarkers in the estimation of prognosis and question o

176 ore, it is essential to identify early-stage biomarkers in those at risk for AD and age-related cogni

177 f perturbation (MDP) score adapted to plasma biomarkers in two distinct databanks from studies that e

178 for fast multiplexed detections of important biomarkers in various body fluids, including urine, sali

179 rform correlation experiments with different biomarkers independently.

180 In this review, biomarkers/indicators for diagnosis of coronavirus disea

181 ly data stability but also the usefulness of biomarker information for subgroup identification enhanc

182 d thus enhance the release of tumor-specific biomarkers into the bloodstream.

183 We assessed associations between baseline biomarkers, IRIS, immune recovery at week 48, and death

184 Whilst the majority of variation in biomarkers is at the individual rather than intersection

185 Analysis of biomarker kinetics (PSP, routine markers) was performed

186 eater in subgroups with baseline coagulation biomarker levels at or above median of the entire study

187 However, plasma biomarkers linked to inflammation (inflammatory response

188 ibed by using linear mixed models, including biomarker [log10(P/B ratio) and/or AMY1 CN] diet-group i

189 The studied general biomarkers, loliolide, cholesterol, and phytol, all show

190 hypothesis testing algorithm that identifies biomarkers' main effects and interactions.

191 As a result, the performance of a prognostic biomarker may be accurate after a specific time of follo

192 A combination of clinical features and biomarkers may aid physicians in identifying patients at

193 d behavioral indicates that these epigenetic biomarkers may serve as complementary measures for the d

194 sed on: (1) CFP only (2 parameters); (2) OCT biomarkers, minimal (3 parameters); (3) OCT biomarkers,

195 hair Cu, and saliva Cr were selected as the biomarkers most strongly associated with VIQ score.

196 LVH (LV septum >11 mm) and elevated cardiac biomarkers (N-terminal pro-B-type natriuretic peptide [>

197 Imaging biomarkers need to be quantitative and user and machine

198 independent prognostic value of a novel MRI biomarker-objectively diagnosed diffuse white matter abn

199 ts potential utility as an easily accessible biomarker of AD pathology.

200 s, highlighting the circuit's potential as a biomarker of dependence severity.

201 We investigated the application of GDF-15 as biomarker of disease severity and response to deoxynucle

202 HFOs are a proposed biomarker of epileptic brain tissue and may also be usef

203 s DNA (ctHPVDNA) is a sensitive and specific biomarker of human papillomavirus (HPV)-associated oroph

204 Serum thromboxane B2 (sTXB2), a validated biomarker of platelet COX-1 activity, and urinary prosta

205 iR-21 was a potential independent prognostic biomarker of poorer OS (HR = 1.27, 95% CI: 1.01, 1.59) a

206 can provide a non-invasive imaging surrogate biomarker of tissue oxygenation status.

207 PES of Abeta-ADCRP is a valid biomarker of underlying amyloid pathology, as demonstrat

208 A methylation data have been used to develop biomarkers of ageing, referred to as 'epigenetic clocks'

209 This Early Biomarkers of AMD (EBAMD) study evaluates serum factors

210 state of the literature on circulating risk biomarkers of APNS is summarized, and key considerations

211 d imaging techniques, and the development of biomarkers of BBB integrity along with systems biology a

212 ion of HCV on bone mineral density (BMD) and biomarkers of bone remodeling in HIV/HCV coinfected pati

213 ological features revealed by scRNA-seq were biomarkers of clinical outcomes in independent cohorts.

214 We aimed to identify serum biomarkers of Crohn's disease and ulcerative colitis tha

215 erceptual reasoning, and act as intermediate biomarkers of disease risk.

216 RNAs and extracellular vesicles as potential biomarkers of disease.

217 intercellular adhesion molecule (ICAM)-1 are biomarkers of endothelial activation, which has been imp

218 p pattern, redox, inflammatory profiles, and biomarkers of endothelial function (NO(2)(-) and ADMA).

219 Our results evaluate novel biomarkers of EpSCC and a putative correlation between t

220 ontrast, there is still a lack of diagnostic biomarkers of functional dystonia and tics, where clinic

221 food group intake (from 75% to 94%) and with biomarkers of gluten ingestion.

222 Among the birth cohort, we measured biomarkers of gut inflammation (myeloperoxidase, neopter

223 VD were recorded and blood was collected for biomarkers of inflammation and immune activation.

224 lammation (AVI) measured by imaging, and key biomarkers of inflammation, lipid, and glucose metabolis

225 oteinase-9) as well as between DS and EC for biomarkers of inflammatory mediators (receptor for advan

226 We aimed to assess whether adding biomarkers of kidney disease to conventional risk factor

227 The C3(hu/hu) mice display elevated biomarkers of kidney dysfunction, glomerulosclerosis, C3

228 that may be considered potential predictive biomarkers of LGG molecular classification.

229 Confirmation of these androgens as alternate biomarkers of near-term pregnancy would carry implicatio

230 r potential therapeutic mediation as well as biomarkers of negative responses to stress following hea

231 everal previously unexplored candidate blood biomarkers of neurological damage with possible clinical

232 l tissue bridges could serve as neuroimaging biomarkers of neuropathic pain and might be used for pre

233 role of the agmatine pathway metabolites as biomarkers of oral health.

234 Net cerebral glucose/lactate exchange, and biomarkers of oxidative and inflammatory stress were als

235 ples were performed to investigate potential biomarkers of response and resistance.

236 patocellular carcinoma (HCC), and predictive biomarkers of response to systemic therapies are lacking

237 Exploratory studies identify potential biomarkers of response.

238 ity to evaluate conventional pharmacodynamic biomarkers of response.

239 ate metabolites using mass spectrometry, and biomarkers of thyroid function [thyroid-stimulating horm

240 SVD biomarkers on the diagnostic brain CT are associated wit

241 n childhood cancers, few have been guided by biomarkers or clinical-grade assays developed to predict

242 ach could potentially lead to new diagnostic biomarkers or inform clinical interventions to help prev

243 Biomarkers or specific clinical symptoms to identify PTL

244 omal glycosidases, is reported to be a vital biomarker overexpressed in primary ovarian cancer cells.

245 rms of the clinical need, COU, assessment of biomarker performance relevant to both the need and COU,

246 itive and accurate quantification of protein biomarkers plays important roles in clinical diagnostics

247 zed functions such as chromatin remodelling, biomarker potential and the recently discovered ncRNA-de

248 ne of the most common clinically used sepsis biomarkers, procalcitonin, and its roles in sepsis manag

249 but necessitates robust clinical evaluation, biomarker profiling and assessment of comorbid factors t

250 In the context of mRNA biomarker profiling, formalin fixed paraffin embedded (F

251 Compared to biomarkers, protocol biopsy yielded more quality-adjuste

252 ough with lower specificity, and this single biomarker provides better sensitivity to non-amnestic Al

253 have functional evidence in humans as blood biomarkers: RAB7A, NPC2, TGFB1, GAP43, ARSB, PER1, GUSB,

254 rotocols to evaluate the excitation index, a biomarker reflecting the contribution of inhibitory and

255 ve surveys (18,859 PSC, 22,695 WRA) from the Biomarkers Reflecting Inflammation and Nutritional Deter

256 Using a multiplex system, we assayed plasma biomarkers related to tubular injury, inflammation, and

257 tery calcification, exercise-induced cardiac biomarker release, myocardial fibrosis, and atrial fibri

258 the COU, and the evidentiary criteria of the biomarker relevant to the COU compared with the current

259 The role of circular RNAs (circRNAs) as biomarkers remains poorly characterized.

260 Cancer biomarker research has become a data-intensive disciplin

261 Amyloid has been the focus of most biomarker research.

262 three main diagnostic pathways with distinct biomarker sequences, in which amyloid-PET and (18)F-FDG-

263 ocus of this communication is on a potential biomarker, short telomere length (TL), that might serve

264 In summary, histological and circulating biomarkers should also be taken into account as potentia

265 These wide-ranging circulating biomarkers show an association with increased disease se

266 We established a biomarker signature and multiple protein ratios that dif

267 ly and sustained immunologic and endothelial biomarker signatures and decreased long-term physical fu

268 evidence from human postmortem and clinical biomarker studies addressing the differential vulnerabil

269 rom the PROVE-HF study (Prospective Study of Biomarkers, Symptom Improvement and Ventricular Remodeli

270 quid biopsy" has driven a shift in molecular biomarker testing away from local pathology laboratories

271 dentified a robust and reproducible ketamine biomarker that is related to the mechanisms of antidepre

272 nclusion: PSMA(TV50) is a promising PSMA PET biomarker that is reproducible and easily quantified by

273 tau181 (p-tau181) is a promising blood-based biomarker that is specific for AD, correlates with cereb

274 and highlights the need for peripheral blood biomarkers that inform about patient lung status and gui

275 a reliable and accessible sample to evaluate biomarkers that may diagnose etiology and predict clinic

276 approved for RCCs has generated a search for biomarkers that might be indicative of treatment respons

277 ay-specific therapeutics in conjunction with biomarkers that predict patient responses.

278 les (EMVs), have been described as sensitive biomarkers that represent disease states and response to

279 graphene electronics, use cases of salivary biomarkers, the performance of existing sensors, and app

280 We use new biomarker thermal maturity indicators to identify seismi

281 creasing, with a parallel rise in the use of biomarkers to guide prognostication and treatment decisi

282 With a lack of noninvasive biomarkers to identify the presence of rejection, endosc

283 These data support the use of proteomic biomarkers to monitor aging trajectories and to identify

284 Currently, we lack reliable biomarkers to predict the development of SNHL in these i

285 rance athletes have raised levels of cardiac biomarkers (troponins and B-type natriuretic peptide) an

286 Using biomarker twice or thrice was cost effective only if bio

287 human blood, and analysis of characteristic biomarkers (type I and III interferons) produced by PBMC

288 In addition, the myogenesis biomarker was a robust binary discriminator of FSHD, DM2

289 A panel of 143 biomarkers was measured by using Luminex technology in s

290 of TMAO and its precursors with disease risk biomarkers were assessed by multivariable linear regress

291 Higher concentrations of serum biomarkers were associated with the development of clini

292 At baseline, all 5 biomarkers were higher than published referent control v

293 Biomarkers were measured in plasma collected preoperativ

294 These biomarkers were subsequently prioritized with a converge

295 hod when seeking to assess panels of protein biomarkers with a view to providing protein profiles to

296 We discovered a compact set of biomarkers with significant improvements on prediction a

297 tions for several glucose- and lipid-related biomarkers with type 2 diabetes and coronary artery dise

298 at 3.0 ppm was used as the pH-sensitive CEST biomarker, with higher MTR(asym) indicating lower pH.

299 ified known as well as novel medical imaging biomarkers without any prior domain knowledge.

300 ucibility and scalability of molecular-based biomarkers would be of great use.